Print Page  Close Window

SEC Filings

SC TO-T/A
ALLERGAN PLC filed this Form SC TO-T/A on 10/17/2016
Entire Document
 
EX-99.(a)(1)(K)

Exhibit (a)(1)(K)

LOGO

NEWS RELEASE

 

  CONTACTS:    ALLERGAN:
     Investors:
     Lisa DeFrancesco
     (862) 261-7152
     Media:
     Mark Marmur
     (862) 261-7558
     Vitae:
     Investors:
     Richard S. Morris
     Chief Financial Officer
     (215) 461-2000
     Westwicke Partners
     John Woolford
     (443) 213-0506
     Media:
     6 Degrees PR
     Tony Plohoros
     (908) 591-2839

Allergan and Vitae Pharmaceuticals Announce Expiration of HSR

Waiting Period for Allergan’s Proposed Acquisition of Vitae

DUBLIN, IRELAND and FORT WASHINGTON, PA – October 17, 2016 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), has expired with respect to Allergan’s pending acquisition of Vitae.

The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter of 2016.